Literature DB >> 33275060

Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients.

Chuanying Geng1, Guangzhong Yang1, Huijuan Wang1, Yin Wu1, Yun Leng1, Huixing Zhou1, Zhiyao Zhang1, Yuan Jian1, Wenming Chen1.   

Abstract

We retrospectively analyzed immunosuppression status in 287 newly diagnosed multiple myeloma (MM) patients and assessed the prognostic value of immunoparesis on survival. Deep immunoparesis was defined that one of uninvolved immunoglobulins was below 50% the lower limit of normal ranges, partial immunoparesis was defined at least two suppressed uninvolved immunoglobulins. We found that patients with deep and partial immunoparesis had a significantly shorter median overall survival (OS) and progression-free survival (PFS). Moreover, deep and partial immunoparesis was a poor prognostic factor for OS and PFS in univariate and multivariable analyses. To reduce the bias between the groups, we performed a 1:1 propensity score matching technique for analysis and found that patients with deep and partial immunoparesis also had shorter OS and PFS. Our study showed that deep and partial immunoparesis can be defined an independent poor prognostic factor for patients with newly diagnosed MM.

Entities:  

Keywords:  Multiple myeloma; immunoparesis; prognostic factors; survival

Mesh:

Substances:

Year:  2020        PMID: 33275060     DOI: 10.1080/10428194.2020.1855345

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

1.  Multiple Myeloma With a Rare Presentation at Preserved Uninvolved Immunoglobulins.

Authors:  Shunsuke Soma
Journal:  Cureus       Date:  2022-05-31

Review 2.  Clinical Considerations for Immunoparesis in Multiple Myeloma.

Authors:  Michael Chahin; Zachery Branham; Ashley Fox; Christian Leurinda; Amany R Keruakous
Journal:  Cancers (Basel)       Date:  2022-05-03       Impact factor: 6.575

3.  Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response.

Authors:  Paola Storti; Valentina Marchica; Rosanna Vescovini; Valentina Franceschi; Luca Russo; Laura Notarfranchi; Vincenzo Raimondi; Denise Toscani; Jessica Burroughs Garcia; Federica Costa; Benedetta Dalla Palma; Nicolas Thomas Iannozzi; Gabriella Sammarelli; Gaetano Donofrio; Nicola Giuliani
Journal:  Oncoimmunology       Date:  2022-09-06       Impact factor: 7.723

4.  Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma.

Authors:  Weimin Huang; Xiaolei Wei; Qi Wei; Yongqiang Wei; Ru Feng
Journal:  Transl Cancer Res       Date:  2021-12       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.